A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

Steven A. Rosenberg, Paul Spiess, Rene Lafreniere

Research output: Contribution to journalArticle

Abstract

The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100% of mice (n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50% of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.

Original languageEnglish (US)
Pages (from-to)1318-1321
Number of pages4
JournalScience
Volume233
Issue number4770
StatePublished - 1986
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Adoptive Immunotherapy
Neoplasms
Cyclophosphamide
Interleukin-2
Lymphokine-Activated Killer Cells
Lung
Liver
Neoplasm Metastasis
Neoplasm Micrometastasis
Adoptive Transfer
Therapeutics
Cell- and Tissue-Based Therapy
Colon
Adenocarcinoma

ASJC Scopus subject areas

  • General

Cite this

Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233(4770), 1318-1321.

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. / Rosenberg, Steven A.; Spiess, Paul; Lafreniere, Rene.

In: Science, Vol. 233, No. 4770, 1986, p. 1318-1321.

Research output: Contribution to journalArticle

Rosenberg, SA, Spiess, P & Lafreniere, R 1986, 'A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes', Science, vol. 233, no. 4770, pp. 1318-1321.
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1321.
Rosenberg, Steven A. ; Spiess, Paul ; Lafreniere, Rene. / A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. In: Science. 1986 ; Vol. 233, No. 4770. pp. 1318-1321.
@article{9f19fdfaf2644f6aa960b084bcd5fa92,
title = "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes",
abstract = "The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100{\%} of mice (n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50{\%} of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.",
author = "Rosenberg, {Steven A.} and Paul Spiess and Rene Lafreniere",
year = "1986",
language = "English (US)",
volume = "233",
pages = "1318--1321",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4770",

}

TY - JOUR

T1 - A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

AU - Rosenberg, Steven A.

AU - Spiess, Paul

AU - Lafreniere, Rene

PY - 1986

Y1 - 1986

N2 - The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100% of mice (n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50% of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.

AB - The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100% of mice (n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50% of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022473607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022473607&partnerID=8YFLogxK

M3 - Article

VL - 233

SP - 1318

EP - 1321

JO - Science

JF - Science

SN - 0036-8075

IS - 4770

ER -